-
Zensar Technologies Limited (BSE: 504067 | NSE: ZENSARTECH) received board approval on July 29, 2026 to merge its two U.S. step‑down subsidiaries, Bridgeview Life Sciences LLC and M3BI LLC, into its wholly‑owned U.S. entity Zensar Technologies Inc., USA.
-
The merging entities have modest sizes: Bridgeview Life Sciences LLC – net worth $0.4 million, turnover $4.74 million; M3BI LLC – net worth $9.32 million, turnover $46.8 million. The receiving subsidiary, Zensar Technologies Inc., USA, holds net worth $74.66 million and turnover $326.96 million.
-
The restructuring involves no cash payment or share‑exchange, and the two subsidiaries will cease to exist as separate entities, leaving Zensar’s overall shareholding pattern unchanged.
-
The transaction is not classified as a related‑party deal, so it is exempt from arm‑length requirements, and is aimed at achieving business synergies, higher operational efficiency, and unified control of Zensar’s U.S. operations.
Frism is a financial information and news discovery platform. We provide factual summaries and data correlations for educational and informational purposes only. Frism does not provide investment advice, buy/sell recommendations, or directional market outlooks. Users should consult a qualified financial advisor before making any investment decisions.
Frism Computing (OPC) Private Limited
#74, 15TH CROSS, JP Nagar III Phase, Bangalore South, Bangalore 560078, Karnataka